Literature DB >> 22659198

Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?

Frank Ruschitzka, Stefano Taddei.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22659198     DOI: 10.1093/eurheartj/ehs108

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  6 in total

1.  Choosing the right angiotensin-receptor blocker for patients with diabetes: still controversial.

Authors:  Mark E Cooper
Journal:  CMAJ       Date:  2013-07-08       Impact factor: 8.262

Review 2.  Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Authors:  Carlos M Ferrario; Adam E Mullick
Journal:  Pharmacol Res       Date:  2017-05-29       Impact factor: 7.658

Review 3.  RAAS inhibition and mortality in hypertension.

Authors:  Roberto Ferrari
Journal:  Glob Cardiol Sci Pract       Date:  2013-11-01

Review 4.  Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk.

Authors:  Csaba András Dézsi; Veronika Szentes
Journal:  Am J Cardiovasc Drugs       Date:  2016-12       Impact factor: 3.571

5.  Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.

Authors:  Marc Evans; Angharad R Morgan; Zaheer Yousef; Gethin Ellis; Umesh Dashora; Dipesh C Patel; Pam Brown; Wasim Hanif; Johnathan N Townend; Naresh Kanumilli; Jim Moore; John P H Wilding; Stephen C Bain
Journal:  Drugs       Date:  2021-06-23       Impact factor: 9.546

6.  The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.

Authors:  Raj Padwal; Mu Lin; Dean T Eurich
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-08-19       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.